AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16873795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes risk score with added impaired fasting glucose or impaired glucose tolerance
Number of subjects: 2677
Study 16873795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes risk score with added low HDL cholesterol and/or high triglycerides
Number of subjects: 2677
Study 16873795 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 2677
Study 14592408 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin transporter (5‐HTT) gene promoter polymorphism
Number of subjects: 78
Study 14592408 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study 10719612 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg AS 195
Number of subjects: 260
Study 10719612 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mg AS 195
Number of subjects: 260
Study 10719612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 10719612 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg AS 195 and 720 mg AS 195
Number of subjects: 260
Study 8923635 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted bone growth stimulation
Number of subjects: 94
Study 8923635 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (Control)
Number of subjects: 94
Study 7897675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active women
Number of subjects: 142
Study 7897675 — intervention group
Group type: COMPARATOR
Intervention: Sexually abstinent women
Number of subjects: 142
Study 7897675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active and abstinent)
Number of subjects: 142
Study 7897675 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger elderly (age 69 or below)
Number of subjects: 142
Study 7897675 — intervention group
Group type: EXPERIMENTAL
Intervention: Older elderly (age 70 or above)
Number of subjects: 142
Study 7897675 — intervention group
Group type: COMPARATOR
Intervention: Sexually active and abstinent women
Number of subjects: 142
Study 3677541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicainoprol (100 mg intravenous infusion)
Number of subjects: 8
Study 3677541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicainoprol (200 mg oral dose)
Number of subjects: 8
Study 3677541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicainoprol (both doses)
Number of subjects: 8
Study 31397211 — intervention group
Group type: EXPERIMENTAL
Intervention: FNMES (fatiguing neuromuscular electrical stimulation)
Number of subjects: 12
Study 31397211 — intervention group
Group type: COMPARATOR
Intervention: CTRL (unfatigued state)
Number of subjects: 12
Study 31397211 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CTRL and FNMES
Number of subjects: 12
Study 29683337 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot mobilization and exercise combined with a toe separator
Number of subjects: 56
Study 29683337 — intervention group
Group type: COMPARATOR
Intervention: No intervention (waiting list)
Number of subjects: 56
Study 24903387 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin inhibitors
Number of subjects: 853
Study 21927036 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen+intermittent non-invasive ventilation (NIV)
Number of subjects: 526
Study 21927036 — intervention group
Group type: COMPARATOR
Intervention: Oxygen supply only
Number of subjects: 526
Study 20402569 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan supplementation
Number of subjects: 20
Study 20402569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18505128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 219
Study 18505128 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 219
Study 15606381 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390
Study 15606381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 12618257 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 104
Study 12618257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 12618257 — intervention group
Group type: EXPERIMENTAL
Intervention: No lorazepam (observational group)
Number of subjects: 104
Study 10319775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane (end-tidal concentration, 0.25%)
Number of subjects: 18
Study 10319775 — intervention group
Group type: COMPARATOR
Intervention: Control (no sevoflurane)
Number of subjects: 18
Study 7588486 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (meso-2,3-dimercaptosuccinic acid)
Number of subjects: 6
Study 7588486 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine administration
Number of subjects: 6
Study 7588486 — intervention group
Group type: COMPARATOR
Intervention: Neomycin administration
Number of subjects: 6
Study 7588486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure
Number of subjects: 6
Study 7588486 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA metabolite
Number of subjects: 6
Study 2277372 — intervention group
Group type: EXPERIMENTAL
Intervention: 80‐mg terconazole suppositories for 3 days
Number of subjects: 0
Study 2277372 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate suppositories for 7 days
Number of subjects: 0
Study 2277372 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories for 7 days
Number of subjects: 0
Study 6985830 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cyclophosphamide, cytosine arabinoside, and methotrexate (CAM)
Number of subjects: 151
Study 6985830 — intervention group
Group type: COMPARATOR
Intervention: Twice daily cytosine arabinoside and thioguanine (AT)
Number of subjects: 151
Study 6985830 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate for both treatments
Number of subjects: 151
Study 6985830 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate for patients surviving three weeks or longer
Number of subjects: 151
Study 6985830 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival for all evaluable patients
Number of subjects: 151
Study 6985830 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival for patients who achieved CR
Number of subjects: 151
Study 6985830 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival for patients who did not achieve CR
Number of subjects: 151
Study 6985830 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity comparison
Number of subjects: 151
Study 31981557 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based HIV self-testing (Oraquick HIV self-test, group demonstration and distribution, and private spaces for interpretation and counselling)
Number of subjects: 5885
Study 31981557 — intervention group
Group type: COMPARATOR
Intervention: Standard provider-initiated testing and counselling (no intervention)
Number of subjects: 5885
Study 31981557 — intervention group
Group type: COMPARATOR
Intervention: Optimised provider-initiated testing and counselling (with additional provider training and morning HIV testing)
Number of subjects: 5885
Study 31981557 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based HIV self-testing
Number of subjects: 5885
Study 31981557 — intervention group
Group type: COMPARATOR
Intervention: Standard provider-initiated testing and counselling and optimised provider-initiated testing and counselling
Number of subjects: 5885
Study 30686693 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 36
Study 30686693 — intervention group
Group type: COMPARATOR
Intervention: Integra
Number of subjects: 36
Study 28474968 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGF + GTR
Number of subjects: 14
Study 28474968 — intervention group
Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 14
Study 26860024 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal Doppler (TED) guidance for fluid management
Number of subjects: 40
Study 26860024 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical monitoring parameters
Number of subjects: 40
Study 23396176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16mg/day
Number of subjects: 102
Study 23396176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 20570081 — intervention group
Group type: EXPERIMENTAL
Intervention: Online video-based education
Number of subjects: 94
Study 20570081 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet-based education
Number of subjects: 94
Study 19584761 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated voice response (AVR) system
Number of subjects: 386
Study 19584761 — intervention group
Group type: COMPARATOR
Intervention: Nurse-assisted symptom management
Number of subjects: 386
Study 16838599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of cardiovascular morbidity and mortality in patients with hypertension
Number of subjects: 139
Study 16838599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction
Number of subjects: 139
Study 16838599 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 139
Study 16838599 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusions for men and women in myocardial infarction studies
Number of subjects: 139
Study 15280524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulphone
Number of subjects: 36
Study 15280524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux modified cellulose
Number of subjects: 36
Study 15280524 — intervention group
Group type: COMPARATOR
Intervention: Control (low-flux polysulphone)
Number of subjects: 36
Study 11758850 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2/day with oral Folinic acid 7.5 mg/dose for 21 days
Number of subjects: 28
Study 11758850 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 28
Study 9212017 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent treatment (Arm 1): vinblastine (VB) 5 mg/M2 I.V. bolus weekly for weeks 1-5, cisplatin (DDP) 100 mg/M2 days 1 and 29, DDP 75 mg/M2 days 50, 71, and 92, with daily RT starting on day 50 (total dose 63 Gy in 34 fractions over 7 weeks).
Number of subjects: 168
Study 9212017 — intervention group
Group type: COMPARATOR
Intervention: Immediate concurrent chemotherapy/radiotherapy (Arm 2): RT started on day 1 (total dose 69.6 Gy in 58 fractions of 1.2 Gy bid, 5 days per week for 6 weeks), DDP 50 mg/M2 i.v. days 1 and 8, oral VP-16 50 mg b.i.d. during the first 10 days of RT, repeated beginning day 29.
Number of subjects: 168
Study 7936019 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Az) and prednisone (group Az)
Number of subjects: 106
Study 7936019 — intervention group
Group type: COMPARATOR
Intervention: Cy and prednisone (group Cy)
Number of subjects: 106
Study 2906171 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 3 days
Number of subjects: 485
Study 2906171 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 7 days
Number of subjects: 485
Study 29289726 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual application of 30% SDF solution
Number of subjects: 371
Study 29289726 — intervention group
Group type: EXPERIMENTAL
Intervention: Three applications of 30% SDF at weekly intervals
Number of subjects: 371
Study 29289726 — intervention group
Group type: COMPARATOR
Intervention: Three applications of 5% NaF varnish at weekly intervals
Number of subjects: 371
Study 28844420 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 70
Study 28844420 — intervention group
Group type: COMPARATOR
Intervention: Continuous interscalene nerve block (CISB)
Number of subjects: 70
Study 26288992 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat bread (FB)
Number of subjects: 10
Study 26288992 — intervention group
Group type: COMPARATOR
Intervention: Control bread (CB)
Number of subjects: 10
Study 26288992 — intervention group
Group type: COMPARATOR
Intervention: Pasta (PA)
Number of subjects: 10
Study 23510291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (not specified)
Number of subjects: 0
Study 23510291 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchor-based method
Number of subjects: 0
Study 23510291 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution-based method
Number of subjects: 0
Study 20653478 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Product (polyethylene glycol 400/propylene glycol-based lubricant eye drops with hydroxypropyl guar)
Number of subjects: 113
Study 20653478 — intervention group
Group type: COMPARATOR
Intervention: Control Product (Optive Lubricant Eye Drops)
Number of subjects: 113
Study 18161033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful forms of attachment (high relationship anxiety and avoidance)
Number of subjects: 92
Study 18161033 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational avoidance
Number of subjects: 92
Study 18161033 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational anxiety
Number of subjects: 92
Study 17196048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25 to 400 mg/day over 8 weeks, continued for 4 additional weeks)
Number of subjects: 287
Study 17196048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 17196048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 287
Study 14751054 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. Anqi
Number of subjects: 80
Study 14751054 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. Anqi and oral consecutive strategy
Number of subjects: 80
Study 14751054 — intervention group
Group type: COMPARATOR
Intervention: i.v. ampicillin and sulbactam
Number of subjects: 80
Study 14751054 — intervention group
Group type: COMPARATOR
Intervention: i.v. cefuroxime
Number of subjects: 80
Study 11202421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) 300 micrograms
Number of subjects: 42
Study 11202421 — intervention group
Group type: COMPARATOR
Intervention: Papaverine 30 mg + phentolamine 1 mg (Control)
Number of subjects: 42
Study 8992678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (900 mg) + Metoclopramide (10 mg)
Number of subjects: 421
Study 8992678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sumatriptan (100 mg)
Number of subjects: 421
Study 8992678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 8992678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate + Metoclopramide
Number of subjects: 421
Study 8992678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 421
Study 1602805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea and interferon alpha (IFN)
Number of subjects: 703
Study 1602805 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 703
Study 1602805 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 703
Study 1602805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic evaluation
Number of subjects: 703
Study 6547041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-permeable lenses
Number of subjects: 9
Study 6547041 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin gas-permeable lens
Number of subjects: 9
Study 6547041 — intervention group
Group type: EXPERIMENTAL
Intervention: Flatter fitting gas-permeable lenses
Number of subjects: 9
Study 6547041 — intervention group
Group type: EXPERIMENTAL
Intervention: All hard lenses studied
Number of subjects: 9
Study 6547041 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no lens)
Number of subjects: 9
Study 6547041 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA lenses
Number of subjects: 9
Study 31542757 — intervention group
Group type: EXPERIMENTAL
Intervention: CPPOpt Guided Therapy (automated CPP target based on cerebrovascular reactivity)
Number of subjects: 0
Study 31542757 — intervention group
Group type: COMPARATOR
Intervention: Brain Trauma Foundation guidelines target (60-70 mm Hg)
Number of subjects: 0
Study 29429928 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) via three 5-minute cycles of upper limb ischemia using a blood pressure cuff
Number of subjects: 30
Study 29429928 — intervention group
Group type: COMPARATOR
Intervention: Control (sham cuff)
Number of subjects: 30
Study 29429928 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (RIPC and Control)
Number of subjects: 30
Study 27150701 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 32
Study 27150701 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 32
Study 24958326 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 547
Study 24958326 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 547
Study 24958326 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 547
Study 24958326 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 50 mg
Number of subjects: 547
Study 24958326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 22930812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 11
Study 22930812 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 11
Study 22930812 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 11
Study 19905859 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and written information
Number of subjects: 76
Study 19905859 — intervention group
Group type: COMPARATOR
Intervention: Verbal information only
Number of subjects: 76
Study 19905859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Verbal and written information, Verbal information only)
Number of subjects: 76
Study 16979793 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based waterless scrub solution (ABWL)
Number of subjects: 1126
Study 16979793 — intervention group
Group type: COMPARATOR
Intervention: Brush-based iodine solution (BBIS)
Number of subjects: 1126
Study 16979793 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based water-aided scrub solution (ABWA)
Number of subjects: 1126
Study 16979793 — intervention group
Group type: EXPERIMENTAL
Intervention: All three solutions
Number of subjects: 1126
Study 14766489 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% KR (Knowledge of Results) during observation
Number of subjects: 54
Study 14766489 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% KR during observation
Number of subjects: 54
Study 14766489 — intervention group
Group type: COMPARATOR
Intervention: Physical practice (Control group)
Number of subjects: 54
Study 12520092 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in alpha-myosin heavy chain mRNA expression
Number of subjects: 47
Study 12520092 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in beta-myosin heavy chain mRNA expression
Number of subjects: 47
Study 12520092 — intervention group
Group type: COMPARATOR
Intervention: Changes in beta(1)- or beta(2)-adrenergic receptor mRNA or protein
Number of subjects: 47
Study 12520092 — intervention group
Group type: COMPARATOR
Intervention: Changes in sarcoplasmic reticulum Ca(2)+ ATPase mRNA expression
Number of subjects: 47
Study 12520092 — intervention group
Group type: COMPARATOR
Intervention: Changes in atrial natriuretic peptide mRNA expression
Number of subjects: 47
Study 9667346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (at least 10 days)
Number of subjects: 213
Study 7806681 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (Augmentin or clindamycin) with scaling and rootplaning
Number of subjects: 21
Study 7806681 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy with scaling and rootplaning
Number of subjects: 21
Study 7806681 — intervention group
Group type: COMPARATOR
Intervention: Scaling and rootplaning alone
Number of subjects: 21
Study 2588997 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of plain 0.5% bupivacaine
Number of subjects: 60
Study 2588997 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of plain 0.5% bupivacaine
Number of subjects: 60
Study 2588997 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of plain 0.5% bupivacaine
Number of subjects: 60
Study 30454074 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-3 operators
Number of subjects: 53
Study 30454074 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-2 operators
Number of subjects: 53
Study 30454074 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-1 operators
Number of subjects: 53
Study 30454074 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis
Number of subjects: 53
Study 30454074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest images available
Number of subjects: 53
Study 28157835 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 25736990 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab (3.0 mg/kg) every 4 weeks for 1 year
Number of subjects: 953
Study 25736990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 953
Study 23179201 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO constituent (50 g)
Number of subjects: 34
Study 23179201 — intervention group
Group type: EXPERIMENTAL
Intervention: New DSF (400 ml)
Number of subjects: 34
Study 23179201 — intervention group
Group type: COMPARATOR
Intervention: Control product (400 ml)
Number of subjects: 34
Study 21948951 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled local analgesia (PCLA): self‐administration of 10 ml of ropivacaine 2 mg ml⁻¹ via the intra‐abdominal catheter for 48 h.
Number of subjects: 50
Study 21948951 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA): infusion of 10 ml h⁻¹ of ropivacaine 1 mg ml⁻¹, fentanyl 2 μg ml⁻¹, and epinephrine 2 μg ml⁻¹ epidurally for 48 h.
Number of subjects: 50
Study 19430766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of Kava (5 tablets per day containing 250 mg of kavalactones/day)
Number of subjects: 60
Study 19430766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60